<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00225745</url>
  </required_header>
  <id_info>
    <org_study_id>DMS 0405</org_study_id>
    <nct_id>NCT00225745</nct_id>
  </id_info>
  <brief_title>Ghrelin Levels in Pancreatic Cancer Patients</brief_title>
  <official_title>Assessment of Plasma Ghrelin Levels in Patients With Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary outcome measure for this study is plasma ghrelin level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary outcome measure for this study is plasma ghrelin level, and the two primary
      comparison are:

        -  Patients with cachexia versus patients without cachexia

        -  Patients with cachexia versus healthy controls
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls</measure>
    <time_frame>prior to treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the role of ghrelin in pathophysiology of cancer cachexia</measure>
    <time_frame>prior to treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To generate hypotheses for future studies and treatment based on the findings</measure>
    <time_frame>prior to treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">72</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Pancreatic cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>One blood draw prior to first treatment</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pancreatic cancer patients who have not received treatment. Healthy age-matched controls.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological proof of pancreatic adenocarcinoma

          -  The control are will include healthy age-matched patients without cancer

          -  The test arm will include patients with pancreatic cancer and they will divided into
             two groups: those with and without weight loss

          -  Patients must have recovered from any major infections and/or surgical procedures

        Exclusion Criteria:

          -  Patients with other serious medical illness like congestive heart failure, thyroid
             disease,liver disease or renal failure - conditions that will alter their nutritional
             state

          -  Patients on appetite stimulant and those receiving total parenteral nutrition

          -  Patients who have undergone gastrectomy or those who have gastric ulcers

          -  Patients receiving active chemotherapy

          -  No prior malignancy except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer or for which patient has been disease free for at
             least five years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Marc Pipas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2005</study_first_submitted>
  <study_first_submitted_qc>September 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ghrelin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

